Aim: To evaluate the extent to which balance in unmeasured characteristics of patients with type 2 diabetes (T2DM) was achieved in claims data, by comparing against more detailed information from linked electronic health records (EHR) data.
| INTRODUCTION
More than 29 million people in the United States currently have diabetes, with~1.7 million new cases every year. 1 Diabetes is associated with several serious complications and is a leading cause of death, with 200 000 related deaths annually. 1, 2 Most diabetes drugs enter the market based on relatively small, short, placebo-controlled randomized controlled trials (RCTs) that often use surrogate outcomes as endpoints, and in which many patients who would receive the drug(s) under routine care are generally underrepresented. In 2008, the US Food and Drug Administration (FDA) mandated larger post-marketing cardiovascular outcome trials (CVOTs) for all new antidiabetic drugs to rule out excess cardiovascular (CV) risk. [3] [4] [5] [6] [7] [8] [9] Although CVOTs provide additional information on the effects of new diabetes therapies, clinicians caring for patients with diabetes continue to face challenges in choosing the best glucose-lowering treatment for their patients because: (1) key information on long-term safety and effectiveness is often unavailable for a considerable time after approval;
(2) the safety of new drugs is poorly established in populations underrepresented in RCTs; and (3) RCTs do not usually include head-to-head comparisons across clinically relevant glucose-lowering options.
Large pharmacoepidemiological studies based on longitudinal insurance claims data, routinely generated in the provision of healthcare for millions of patients, are increasingly used to fill these gaps and provide information on the comparative effectiveness and safety of glucose-lowering agents in real-world populations. [10] [11] [12] [13] These studies are often criticized, however, because of the lack of information on critical clinical characteristics, such as body mass index (BMI), exact duration of diabetes, and glycated haemoglobin (HbA1c) levels, which in the absence of randomization could remain unbalanced across comparison groups, even after adjustment, and thus lead to biased treatment effect estimates.
It is often assumed that the absence of this information in pharmacoepidemiological studies could be largely addressed by the application of state-of-the-art study design and analytical choices. For example, in the context of safety and effectiveness research on diabetes therapy, using a new-user study design enhanced by the proper choice of an active comparator drug, which tends to be used by patients at a similar stage of diabetes, could better distinguish drug effects from diabetes disease effects. 14, 15 Additionally, adjusting analyses via propensity score (PS) matching could leverage the vast information recorded in large claims databases to estimate treatment effects in a population with clinical equipoise regarding many aspects of care, including characteristics that may act as proxies for unmeasured information. 16, 17 These strategies combined are thought to improve balance in patient characteristics, and thus mitigate the potential confounding in non-interventional pharmacoepidemiological studies.
With the growing proliferation of digital information in healthcare, subsets of administrative data can be successfully linked to electronic health records (EHR), which routinely collect important clinical information, to assess the balance of these characteristics across exposure groups identified in claims. Thus, we sought to evaluate the extent to which balance in unmeasured patient characteristics was achieved in claims data, by comparing against more detailed information from EHR data.
| METHODS

| Overview of monitoring programme
This study was preemptively conducted in the context of an ongoing multi-year monitoring programme aimed at assessing linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, compared with 3 groups of oral antidiabetic drugs, with regard to several safety and effectiveness outcomes (NCT02197078, EUPAS5790 Oedema, % Dual therapy with metformin was defined as concomitant initiation or current use of metformin on the day of linagliptin or comparator initiation, i.e., having metformin days' supply overlapping with the day of drug initiation, and no use of other glucose-lowering agents.
b Current use was defined as having days' supply available for an agent on the day of linagliptin or comparator initiation without a grace period.
To control for imbalances in patient characteristics between treatment groups, in three separate multivariable logistic regression models we estimated exposure PSs as the predicted probability of receiving the treatment of interest (ie, linagliptin vs each comparator) conditional on over 100 claims-based subjects' baseline characteristics, 19 identified during the 6 months before and including the cohort entry date.
Emphasis was placed on the identification of claims-measured proxies of diabetes severity and duration (eg, number of glucose-lowering medications at index date and specific past or concurrent diabetes therapy, diabetic nephropathy, neuropathy, retinopathy, diabetic foot, number of HbA1c or glucose tests ordered, etc.). Other patient characteristics included demographics, presence of other comorbidities, use of medications, and indicators of healthcare utilization as proxy for overall disease state and care intensity ( Table 1 and Table S1 ) Comorbidities were defined using ICD-9 codes and CPT-4 codes. Exposure groups were 1:1 matched on their PS using nearest-neighbour matching without replacement with a maximum caliper of 0.05. 20 Matching was performed within calendar quarters to account for changing prescribing behaviours over time, as selective prescribing of a new medication may be strong in the early marketing period and characteristics of patients receiving the new agent may shift quickly. 21 
| Claims-EHR linkage and EHR-based clinical characteristics
For a subset of patients enrolled in the claims-based study population before and after PS-matching, insurance claims were enriched with additional data obtained through linkage with EHR, performed by Truven Health Analytics. EHR information was contributed by select clinics providing care to MarketScan beneficiaries. In order to maintain patient confidentiality, the linkage was performed through variables such as the patient's gender, month, year of birth and 3-digit ZIP code of residence. In large ZIP code areas, additional criteria, such as dates of office visits, were used to discriminate true from false matches. 22 Within the linked subset, several EHR-based clinical characteristics related to T2DM treatment that may also predict the primary CVD outcome of the monitoring programme were identified and used in the analyses. EHR-based covariates were captured prior to cohort entry and included health behaviours (smoking status and BMI), duration of diabetes (the earliest record for a T2DM diagnosis in the EHR using all available information prior to treatment initiation), laboratory test results (baseline HbA1c, creatinine, estimated glomerular filtration rate
[eGFR] 23 and lipid levels), and blood pressure (systolic and diastolic levels). If multiple recordings of EHR-based covariates were available, we only considered the value closest to the day of cohort entry.
| Statistical analysis
To assess whether the claims-EHR-linked subset was representative of the overall study population, we compared claims-based characteristics among study participants for whom EHR data were available to patients without EHR data available, and evaluated covariate balance using standardized differences (SDs). Similarly, to assess the presence of potential confounding associated with unmeasured clinical characteristics in the claims-based study population, we cross-tabulated baseline patient characteristics by each pair of linagliptin or its comparator and evaluated the balance of EHR-based covariates between exposure groups, before and after PS-matching, via SD values. Meaningful imbalances in SDs were defined as differences >0.1.
24
In a secondary analysis, we quantified the potential bias associated with observed imbalances, through hypothetical scenarios built on varying assumptions of exposure-outcome and confounderoutcome associations. 25 
| RESULTS
After applying inclusion and exclusion criteria, we identified a claims- Claims-based patient characteristics between study participants for whom EHR data were available and patients without available EHR data were well balanced (SD <0.1), suggesting the EHR-linked subset was representative of the overall study population (Table S2) .
Independently of EHR data availability, drug initiators were aged 55 years, and were more likely to be male, to be on therapy with one other antidiabetic medication, and to have low prevalence of diabetes complications and other comorbidities. Minor imbalances were noted for a few characteristics, namely, total number of distinct medications prescribed, number of physician visits, and number of laboratory tests ordered, all of which were more prevalent amongst the EHR-linked subset.
Within the overall study population, claims-based patient characteristics between exposure groups in each comparison appeared reasonably well balanced even before PS-matching, with initiators of linagliptin and comparator agents having similar mean age and prevalence of diabetes complications (Table 1 and Table S1 ). Compared with initiators of other agents, linagliptin initiators had a similar mean age (~55 years), gender distribution (~60% males), use of antidiabetic medications (>50% started therapy in addition to one other antidiabetic medication), and prevalence of most diabetes complications; for example, diabetic nephropathy, neuropathy, retinopathy and diabetic
foot. Yet, we also noted a few imbalances. Specifically, compared with initiators of other agents linagliptin initiators were more likely to have a greater overall burden of comorbidities, as measured by the Romano modification of the Charlson comorbidity score, 26 a higher prevalence of select comorbidities, such as kidney disease and congestive heart failure, a lower utilization of metformin combination therapy, and a higher utilization of overall medications (Table 1 and Table S1 ).
After PS-matching, all claims-based characteristics were well balanced between linagliptin initiators and initiators of comparator agents.
As for claims-based characteristics in the overall population, within the EHR-linked subset, EHR-based covariates appeared reasonably well balanced before PS-matching (Table 2 and Table S3 ).
Smoking status, BMI, diabetes duration, and blood pressure, were largely well balanced across comparisons, with most of the population being a never-smoker, being obese or severely obese, having diabetes duration <3 years, and being normotensive. A few imbalances with ensures that baseline covariates are assessed before treatment initiation and are not affected by treatment itself. 12, 28 These choices resulted in fair balance in EHR-based covariates even before PS-matching, as a testament to the major role played by a proper study design for the achievement of overall study validity. 14, 15 Once adequate study design choices have been made, our findings also suggest that the inclusion of a large number of patient characteristics in the estimation of the PS can further lead to balance of unmeasured but correlated variables by proxy, and as a result, mitigate confounding by the same unmeasured covariates, as previously observed. 29 In the present study, we considered many aspects of care, including several proxies of diabetes progression, in the calculation of the PS, and used the estimated score to match study participants with expected clinical equipoise on these characteristics, that is, excluding patients who will always or never receive therapy because of indications or contraindications. Another strength is that EHR information on potential confounders was recorded prior to diabetes therapy initiation, and thus the accuracy and completeness of the data were unlikely to be related to treatment initiation.
We were able to evaluate covariate balance only within an EHRlinked subset corresponding to 4.3% of the overall study population, which could have undermined the generalizability of our findings to the main population; however, the comparability in claims-based covariate distribution between the EHR-linked subset and the overall study population, and the random nature of the EHR sampling, sug- Another limitation is that potential misclassification of EHR-based covariates (eg, under-diagnosis of conditions such as kidney disease) cannot be ruled out. We also observed a proportion of patients with missing EHR information (ranging from~25% to 60%, depending on the variable), although the mechanism underlying the missingness appeared to be non-differential between exposure groups. Finally, EHR linkage was not available for all matched pairs in the PSmatched population, essentially breaking the 1:1 matching for a small proportion of the EHR-linked subset which could have contributed to minor residual imbalances.
In conclusion, in a claims-based study population of patients with T2DM linked to EHR data for a representative subset, we found that choosing appropriate comparison groups with a new user design and using PS-matching on many proxies of diabetes progression substantially improves balance in diabetes risk factors typically unmeasured in claims datasets.
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